Abstract
Introduction

Somatostatin (SST) is a cyclic peptide and a notable physiological regulator of neuroendocrine function across multiple organ systems [1]. It is produced by the hypothalamus, throughout the central nervous system (CNS), and in different peripheral organs including gastrointestinal tract (GIT) and pancreas
. The SST gene is located in chromosome 3q28 and encodes a 116 amino acid preprohormone (preprosomatostatin) which contains the 92 amino acid SST prohormone (prosomatostatin) [4] . Prosomatostatin is the precursor peptide of the two biologically active SST forms: 14 amino acid long SST-14 and amino-terminus extended SST-28 [5] . The biological roles of the two SST isoforms strongly overlap and the relative proportions of SST-14 to change between different tissues [6, 7] . SST-14 is the predominant form in the brain (including the hypothalamus), whereas SST-28 is the major form in the GIT, especially the duodenum and jejunum [8] .
SST has a broad range of biological actions including inhibition of exocrine secretions (gastric acid production, pancreatic [3, [9] [10] [11] [12] . In the CNS, SST is highly expressed in the cortex, lateral septum, extended amygdala, reticular nucleus of the thalamus, hippocampus and many brain stem nuclei where it acts as a neurotransmitter and neuromodulator [8, 13] [4, 10, 12] . Sequence homology is 39-57% among the five subtypes [12] . [19, 21, 22] . There are two different isoforms of SSTR2 (SSTR2A and SSTR2B) produced via alternative splicing [23, 24] and SSTR2B is almost unexpressed in human beings [9] . SSTRs bind natural peptides, SST-14 and SST-28, with similar high affinity (nM range) [10] . However, SSTR5 has a 10-fold higher affinity for SST-28 compared to SSTR2A or SSTR3, which have a higher affinity to .
enzyme, bile and colonic fluid secretion) and endocrine secretions in the pituitary (GH, TSH, prolactin), pancreas (insulin, gastrin, glucagon) and GIT (cholecystokinin, vasoactive intestinal peptide and secretin)
SSTRs belong to the G-protein coupled receptor (GPCR) superfamily and are extensively distributed throughout many tissues ranging from the CNS to the pancreas and gut, and also in pituitary, kidney, thyroid, lung and immune cells [19], besides their presence in various cancer cells. The majority of tumours (and also normal tissues) express SSTR2, followed by SSTR1, SSTR5 and SSTR3, whereas SSTR4 is the least expressed subtype
Investigations on SSTR signalling and determining the specific function of each SSTR pose difficulty due to various factors in experimental settings. First, the different SSTR subtypes can coexist in the same tissue and even on the same cell at different densities, and which type of signalling becomes predominant in the given cell depends on the cell-specific distribution of SSTR subtypes and signalling elements [4] . Second, experimental studies on SSTRs are generally performed in cell lines from different species and the significance of the findings of these studies for normal and malignant human tissues remains to be determined. Fortunately, a remarkable degree of structural conservation across species has been reported for SSTRs [13] . SSTR1 is the most highly conserved, with 97% identity between human beings and rat, whereas the sequence of SSTR5 is the most divergent, with 81% identity between human beings and rat [13] . There is 92%, 86% and 89% identity between human and rat SSTR2, SSTR3 and SSTR4, respectively [6, 26] 
The somatostatin receptor as a GPCR
GPCRs are characterized by a core of seven transmembrane ␣-helices connected by three intra-and three extracellular loops [4] . The [53] . Although GIPs and RGS have been found to interact with distinct recombinant SSTRs [54, 55] , the real functional role of these complexes in native systems with respect to signal transduction is still not very well documented. SST binding is known to be rapidly followed by phosphorylation of SSTR1, SSTR2A and SSTR3 by GRKs [56] [57] [58] . The GRK family consists of six serine-threonine kinases that specifically bind to and phosphorylate agonist-activated GPCRs [59, 60] . GRKs [66] . However, not all SSTRs internalize equally after agonist binding [67, 68] [56, 72, 73] .
Not only the nature of the SSTR subtypes present in a particular cellular environment but also the nature of the agonist is a critical determinant of the tissue response to SST [65] . In GPCRs, including SSTR signalling, a classical two-state model was accepted for a long time. This model proposed that the binding of an agonist shifted an equilibrium from 'the inactive', basal conformation of a receptor to 'the active' conformation by stabilizing the latter [74, 75] . According to this model the relative potencies of agonists for inducing any two biological effects from a single receptor would be the same [74, 75] . In studies evaluating receptor dynamics, analogue activities were generally retrieved from only one or two measurements; such as inhibition of hormone secretion or modulation of second messenger production [65] . Then these measurements were used to indicate the overall potency and efficacy of the analogues under investigation [65] . However, with this model it was not possible to explain the effect of many agonists which might induce only some of the possible responses following receptor activation, or to activate two effectors with different relative potencies [65] . New terms including 'functionally selective agonism' have been used to describe the idea that agonists can selectively activate different signalling pathways and responses via a single GPCR [65] . Described in detail in an elegant review by Schonbrunn, such selective signalling is explained by a model in which agonists not only exhibit different affinities for a receptor, but they also stabilize different active receptor conformations [65] . These differentially activated receptor structures determine the interaction of the receptor with the cytoplasmic proteins, including G proteins, kinases and phosphatases, and additionally its regulation by GRKs or arrestins [65] . Thus, this model predicts that in any given cell type, the relative potencies or efficacies of agonists for various biological effects may differ even though their actions are triggered by a single receptor subtype [65] . Meanwhile, it is clear that signalling by, and regulation of, SSTR2, SSTR4 and SSTR5, are sensitive to the nature of the specific activating agonist [65] . Thus, a basic and simple assumption that all agonists are functionally equivalent and produce the same spectrum of effects at individual SSTRs can not be accepted any longer [65] .
Receptor [80, 81] . Even in the same family, the behaviour of receptors can be opposite, as reported for SSTR2 and SSTR5, whose dimerization decreases or increases, respectively, after ligand binding [82, 83] [76] , human SSTR1 and SSTR5 [30] , human SSTR4 and SSTR5 [84] and human SSTR2 and SSTR5, some being demonstrated under certain conditions [85] . Heterodimerization among these SSTR subtypes causes both distinct effects on SSTR functioning and modifies the endocytic process of these receptors [33] . An example for this may be the interaction between SSTR2 and SSTR3, which results in both inactivation and impaired internalization of SSTR3 [76] . 
Cotransfection of human SSTR1 and SSTR5 in Chinese hamster ovary (CHO)-K1 cells results in an increased ligand affinity for SST [30]. On the other hand, internalization of this heterodimer is better in response to a specific SSTR1 ligand and smaller in response to a specific SSTR5 ligand compared to monomer forms of these receptors [30]. Stabilization of human
Anti-tumour effects of somatostatin
There are a number of mechanisms responsible for the antitumour actions of SST [88] . [91] .
During the initial stages of metastatic development, malignant cells must enter the lymphatic and systemic circulation by detaching from adjacent cells and then attaching to and disrupting the endothelial basement membrane [92, 93] . SST has been shown to reduce the adhesion of carcino-sarcoma cells to blood vessels and thus attenuate the metastatic potential of these tumours [94] [96] . 
. When an agonist activates GPCR, the GDP-bound G␣␤␥ heterotrimer interacts with the receptor and the ␣ subunit decreases the affinity for GDP [41]. As the GTP concentration is higher in the cytoplasm, this results in substitution of GDP with GTP. Thereafter, G␣ protein dissociates both from the receptor and ␤␦ subunits and both modulate the activity of several intracellular pathways [41]. Among these there are several key enzymes, including PTPs, adenylyl cyclase (AC) and pathways including mitogen-activated protein kinase (MAPK) and phosphoinositol-3-kinase (PI3K)/Akt, which are modulated along with reduction of the Ca
ϩϩ influx through voltage sensitive channels and the activation of K ϩ channels [98] . (Fig. 1) , and control of the activity of another important downstream signalling pathway, PI3K/Akt (Fig. 2) [101] [104] [105] [106] [107] , for DEP-1 with PDGF and the vascular endothelial growth factor receptor [108, 109] and for PTP1B with the EGF receptor [110] .
Phosphotyrosine phosphatases and their action on MAPK and PI3K/Akt pathways
In the human genome around 107 PTPs have been identified, which includes 38 so-called 'classical PTPs' with an elevated specificity for phosphotyrosines [99]. In studies using cells transfected with individual SSTR subtypes, all the five members of this receptor subfamily have been shown to couple to a number of PTPs, including the SH2 domain-containing cytosolic tyrosine phosphatases (SHP-1 and SHP-2), and the density-enhanced protein-tyrosine phosphatase-1 (DEP-1/PTP) [38, 100]. SST also couples to protein-serine/threonine phosphatases (PP), including PP2A and PP2B (calcineurin). The anti-proliferative action of SST-activated PTPs depends on altered growth factor signalling through the selective dephosphorylation and inactivation of their receptors, plus inhibition of one of the most important MAPK pathways for cell proliferation, namely the extracellular signal-regulated protein kinase 1/2 (ERK 1/2) pathway
. The inhibition of the ERK 1/2 pathway can occur either indirectly via the inhibition of the growth factor tyrosine kinase receptors or directly by dephosphorylating ERK 1/2 or by hyperactivation of ERK 1/2 (see below) [102, 103]. Such altered growth factor signalling through the selective dephosphorylation and inactivation of their receptors have been reported for SHP-1 with the insulin receptor, for SHP-2 with the insulin, EGF and platelet-derived growth factor (PDGF) receptor
SSTR activation of SHP-1 was reported to induce arrest of cell proliferation in human pituitary adenomas [111] , GH3 rat pituitary tumour cells [112] , in different tumour cell lines derived from pancreatic cancers (MIA-PaCa-2, PANC-1, PC-1) and from thyroid medullary carcinoma, among others [79, 101, [113] [114] [115] . SHP-1 activation is the critical step for SSTR2-mediated anti-proliferative signalling [101, 116] . Tyrosine phosphorylated SSTR2 interacts with and activates SHP-2 and Src, a cytosolic tyrosine kinase, inducing consequent SHP-1 recruitment and activation [117] (Fig. 1) . [106] .
In CHO cells, SST-activated SHP-1 rapidly associates to the insulin receptor causing a tyrosine dephosphorylation of both the receptor itself and its substrates (i.e. IRS-1, Shc) leading to a negative modulation of insulin mitogenic signalling
Additionally, SHP-1 inhibits the ERK 1/2 pathway by directly or indirectly dephosphorylating ERK 1/2 [4], causes overexpression of the cyclin-dependent kinase inhibitor p 27kip1 and an increase in hypophosphorylated retinoblastoma gene product (Rb) which, taken together, leads to inhibition of the entry in the S phase of the cell cycle and accumulation of the cells in G1 [118]. In pancreatic and pituitary tumour cells SSTR2 activation of SHP-1 was found to be involved in the p53-independent induction of apoptosis [119-121]. Additionally, a completely novel mechanism was identified in NIH3T3 (NIH Swiss mouse embryonic fibroblast cell line) cells in which the activation of SHP-1 by SSTR2 activates the transcription factor nuclear factor-B causing an inhibition of the antiapoptotic effects of the MAP kinase, Jun N-terminal kinase and, in turn, hyperactivation of caspase 8 and apoptosis [122]. Of interest in this regard is the finding that SSTR2 also affects the apoptosis induced by death receptors, sensitizing the cells to tumour necrosis factor (TNF)-␣-and TRAIL-mediated responses through the up-regulation of their receptors: death receptor 4 and TNFR1 [119]. In essence, SHP-1 activity was also involved in SSTR3-dependent apoptosis in transfected CHO cells, but this time by involving the induction of p53 and the subsequent activation of the pro-apoptotic protein Bax [123]. In GH3 cells, SSTR2-induced activation of SHP-1 causes the dephosphorylation of p85 and hence the inhibition of PI3K activity [101]. As would be expected, inhibition of PI3K activity causes inhibition of PDK1 and Akt activities, which in turn results in the activation of the glycogen synthase kinase-3␤ (GSK-3␤) (Fig. 2). Theodoropoulou and colleagues have reported that the enhanced GSK-3␤ activity up-regulated the expression of Zac1 gene, which ultimately induced growth arrest [101]. Zac1 is highly expressed in normal pituitary, mammary and ovarian glands but is down-regulated in pituitary, breast and ovarian tumours, suggesting that it might act as a tumour suppressor gene [101]. Their further study investigating the immunoreactivity of Zac1 protein in tumour tissues of patients treated with SST analogues prior to surgery has also revealed a significantly positive correlation between strong Zac1
immunoreactivity and IGF-I normalization and the presence of tumour shrinkage after SST analogue treatment [124] . The other PTP, SHP-2, was involved in the anti-proliferative activity of SST following SSTR1 [102, 125] , SSTR2, SSTR3 and SSTR4 activation [126] . Besides dephosphorylating and inactivating the tyrosine kinase receptors for insulin and EGF [104, 107] , SHP-2 is involved in cell growth arrest [125] (Fig. 1) . It is known that the effects of ERK 1/2 on cell proliferation are also related to the duration and intensity of ERK 1/2 activation, and hyperactivation of the ERK 1/2 pathway can also cause cell cycle arrest [127] .
In light of this knowledge, it is now known that the activation of both SSTR1 and SSTR2 induces cell cycle arrest via the hyperactivation of ERK 1/2 and the up-regulation of p21
cip1/waf1 and p27 kip1 , respectively [102, 103] . In particular, the activation [128, 129] . In addition, besides SHP-1 and SHP-2 activity, another delayed and long-lasting PTP activity was also induced following SST treatment [125] . As opposed to SHP-1 and SHP-2 which are cytosolic, non-membrane PTPs, one of these PTPs was identified in a receptor like PTP named DEP-1 in human beings (PTP in rats), whose tumour suppressor role had already been established [130] . It was suggested that, in endothelial cells, DEP-1/PTP represents a possible effector of SSTR to inhibit tumoral angiogenesis and the activity of DEP-1 seems fundamental in blocking endothelial cell migration and proliferation [109, 131, 132] ; the in vivo and in vitro anti-angiogenic activity of SST was dependent on the activation of PTPs [133, 134] . SSTR1-activated DEP-1 was shown to inhibit ERK 1/2 in PC C13 thyroid cells and SSTR1-, SSTR2-and SSTR5-activated DEP-1 was shown to inhibit ERK 1/2 in glioma cells [135] . In CHO-K1 cells expressing SSTR1, a large multimeric protein aggregation composed of the G protein, Jak2, [79] . [137] . All SSTR subtypes inhibit AC via the pertussis toxin-sensitive G-protein family, Gi/Go [65] . Specifically, SSTR2 decreased AC activity/cAMP accumulation in BON-1 (pancreatic NET cell line) and SH-SY5Y (neuroblastoma cell line) cells [138, 139] and in pituitary cells [140] . The stimulation of SSTR3 in CHO and HEK-293 cells decreases AC activity [141, 142] . SSTR5 decreased cAMP levels in human SH-SY5Y and BON-1 cells [138, 139] [150, 154, 156] . Activation of PLC and IP3 production by SSTR4 was also observed in transfected COS (monkey kidney cell line) cells [157] . Phospholipase A2 (PLA2) is a cytoplasmic enzyme that hydrolyses triglycerol to form arachidonic acid, the metabolites of which have been shown to regulate different physiological and pathological functions [158, 159] . SST coupling negatively to arachidonate release has been shown in the rat anterior pituitary gland [160] . In contrast, SST has been suggested to generate arachidonic acid metabolites in rat GH4C1 cells, through pertussis toxin-sensitive G proteins [161] . Nevertheless, in a few cases SST was reported to induce cell proliferation through SSTR4 activation, which was observed to increase ERK 1/2 activity and, in turn, regulate PLA2 activation [162] .
of SSTR1-induced ERK 1/2 pathway involved Src/SHP-2/PI3K/ras/Raf-1/MEK (mitogen-activated protein) [102], the
Fig. 1 A simplified diagram of the Ras/ERK pathway and SST effects through PTPs, SHP-1 and SHP-2. Yellow lines show activation, red lines show inhibition of the corresponding protein. Note SHP-1 and SHP-2 inhibition of growth factor receptors, SHP-1 inhibition of ERK 1/2, SHP-2 inhibition of Raf kinase shown in blue lines. Src and SHP-2 activates SHP-1. As a result, SHP-1 and SHP-2 lead the cells to accumulate in G1 phase and inhibit entry in
Starting with cAMP, the negative modulation of AC activity leads to the regulation of cAMP production. This also has a negative impact on various downstream elements, in particular, protein kinase A, which is the major target for cAMP in the cell. The inhibition of AC by SST has been demonstrated in many different systems, including human pituitary adenomas
Moreover, also other MAPKs, more frequently associated to the induction of cell growth arrest, are regulated by SST: p38 is activated by SSTR2 and SSTR4 in CHO-K1 cells [98] and Jun Nterminal kinase is activated by SSTR5 [163] .
SST was reported to regulate nitric oxide generation through the activation of both the endothelial and neuronal nitric oxide synthases (eNOS and nNOS, respectively). However, SST has been shown to have a dual effect on the release of nitric oxide. In different paradigms it has been shown to increase or inhibit nitric oxide levels via the involvement of different receptor subtypes and intracellular pathways [164] . SSTR2 caused a SHP-1-dependent dephosphorylation and activation of nNOS in mouse pancreas acini cells, which leads to increased nitric oxide production [165] . Nitric oxide is a major regulator of soluble guanylyl cyclase [28] . Guanylyl cyclase converts GTP to cyclic nucleotide guanosine monophosphate (cGMP), which is a regulatory mediator of cell proliferation [166] . The increased nitric oxide production in these cells results in activation of cGMP levels which is believed to be instrumental in growth arrest [164, 165] . cGMP exerts its effects via modulation of cGMP-dependent protein kinase (PKG), cGMPgated ionic channels and cyclic nucleotide phosphodiesterases [167, 168] . Conversely, in a study by Cordelier and 
colleagues, inhibition of nNOS activity and a reduction in intracellular cGMP
formation which resulted in cell growth arrest was observed in CHO cells expressing SSTR5 [169] . It was noted in this study that SSTR5 inhibits cell proliferation through SSTR5-mediated Src activation and subsequent nNOS tyrosine phosphorylation and inactivation, leading to a decrease of cGMP production and subsequent MAPK inhibition [166, 169] . SST-induced negative regulation of nitric oxide was also shown to be implicated in the inhibition of tumour angiogenesis and growth via the SSTR3-mediated negative regulation of eNOS [170] .
The inhibition of Na 
